Akebia Therapeutics, Inc., a biotechnology company headquartered in Cambridge, Massachusetts, continues to focus on the development and distribution of innovative therapeutics targeting kidney diseases. The company’s primary area of research involves hypoxia inducible factor (HIF) based treatments, aiming to address unmet medical needs in this domain. Akebia Therapeutics serves its clientele primarily within the United States and maintains an online presence through its website, www.akebia.com .
As of March 7, 2026, Akebia Therapeutics has not reported any new developments. The latest public communication from the company was a press release dated March 3, 2026, announcing its participation in the Leerink Partners 2026 Global Healthcare Conference. This event underscores the company’s ongoing engagement with the broader healthcare community and its commitment to advancing its research initiatives.
Financially, Akebia Therapeutics is listed on the Nasdaq stock exchange, where it has been publicly traded since March 20, 2014. The company’s stock closed at $1.27 on March 5, 2026. This price is situated between the 52-week low of $1.14, recorded on February 19, 2026, and the 52-week high of $4.079, recorded on July 10, 2025. This range highlights a moderate level of volatility, with the stock price having fluctuated significantly over the past year.
The company’s market capitalization stands at approximately $318.78 million USD, reflecting its current market valuation. However, the price-to-earnings (P/E) ratio is notably negative at -66.33, indicating that the company is not currently generating profits. This negative P/E ratio is typical for many biotechnology firms in the development phase, where significant investments in research and development often precede revenue generation.
In summary, Akebia Therapeutics remains focused on its strategic objectives within the biotechnology sector, particularly in the realm of kidney disease therapeutics. Despite the absence of recent breakthroughs, the company’s participation in industry conferences and its ongoing research efforts continue to position it as a key player in the healthcare landscape. Investors and stakeholders are likely to monitor the company’s progress closely, particularly in light of its historical stock performance and current market valuation.
